| Translation control of the immune checkpoint in cancer and its therapeutic targeting Y Xu, M Poggio, HY Jin, Z Shi, CM Forester, Y Wang, CR Stumpf, L Xue, ... Nature medicine 25 (2), 301-311, 2019 | 215 | 2019 |
| Transfection of microRNA mimics should be used with caution HY Jin, A Gonzalez-Martin, AV Miletic, M Lai, S Knight, M Sabouri-Ghomi, ... Frontiers in genetics 6, 340, 2015 | 204 | 2015 |
| MicroRNAs of the miR-17∼ 92 family are critical regulators of T FH differentiation SG Kang, WH Liu, P Lu, HY Jin, HW Lim, J Shepherd, D Fremgen, ... Nature immunology 14 (8), 849-857, 2013 | 199 | 2013 |
| The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression K Ichiyama, A Gonzalez-Martin, BS Kim, HY Jin, W Jin, W Xu, ... Immunity 44 (6), 1284-1298, 2016 | 167 | 2016 |
| MicroRNA‐17∼ 92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways HY Jin, H Oda, M Lai, RL Skalsky, K Bethel, J Shepherd, SG Kang, ... The EMBO journal 32 (17), 2377-2391, 2013 | 151 | 2013 |
| A miR-155–Peli1–c-Rel pathway controls the generation and function of T follicular helper cells WH Liu, SG Kang, Z Huang, CJ Wu, HY Jin, CJ Maine, Y Liu, J Shepherd, ... Journal of Experimental Medicine 213 (9), 1901-1919, 2016 | 75 | 2016 |
| Regulation of B-cell development and tolerance by different members of the miR-17∼ 92 family microRNAs M Lai, A Gonzalez-Martin, AB Cooper, H Oda, HY Jin, J Shepherd, L He, ... Nature communications 7, 2016 | 75 | 2016 |
| MicroRNA mechanisms of action: what have we learned from mice? HY Jin, C Xiao Frontiers in genetics 6, 328, 2015 | 51 | 2015 |
| Differential Sensitivity of Target Genes to Translational Repression by miR-17~ 92 HY Jin, H Oda, P Chen, C Yang, X Zhou, SG Kang, E Valentine, ... PLoS genetics 13 (2), e1006623, 2017 | 39 | 2017 |
| Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia O Al-Sawaf, C Zhang, HY Jin, S Robrecht, Y Choi, S Balasubramanian, ... Nature Communications 14 (1), 2147, 2023 | 38 | 2023 |
| microRNA-17~ 92 is a powerful cancer driver and a therapeutic target HY Jin, M Lai, C Xiao Cell Cycle 13 (4), 495-496, 2014 | 26 | 2014 |
| The virion-associated open reading frame 49 of murine gammaherpesvirus 68 promotes viral replication both in vitro and in vivo as a derepressor of RTA CW Noh, HJ Cho, HR Kang, HY Jin, S Lee, H Deng, TT Wu, ... Journal of Virology 86 (2), 1109-1118, 2012 | 25 | 2012 |
| Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc I Kandela, HY Jin, K Owen, Reproducibility Project: Cancer Biology Elife 4, 904-917, 2015 | 20 | 2015 |
| An integrated polysome profiling and ribosome profiling method to investigate in vivo translatome HY Jin, C Xiao Next generation sequencing: Methods and protocols, 1-18, 2018 | 17 | 2018 |
| High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms HY Jin, Y Tudor, K Choi, Z Shao, BA Sparling, JG McGivern, A Symons SLAS DISCOVERY: Advancing the Science of Drug Discovery 25 (2), 215-222, 2020 | 13 | 2020 |
| Phc2 controls hematopoietic stem and progenitor cell mobilization from bone marrow by repressing Vcam1 expression J Bae, SP Choi, K Isono, JY Lee, SW Park, CY Choi, J Han, SH Kim, ... Nature communications 10 (1), 3496, 2019 | 12 | 2019 |
| Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N AA Rahman, A Soto-Avellaneda, HY Jin, I Stojkovska, NK Lai, JE Albright, ... Neuroscience 441, 33-45, 2020 | 9 | 2020 |
| Agonist Antibody Converts Stem Cells into Migrating Brown Adipocyte-Like Cells in Heart KH Han, BM Arlian, CW Lin, HY Jin, GH Kang, S Lee, PCW Lee, ... Cells 9 (1), 256, 2020 | 5 | 2020 |
| Concurrent PI3K and NF-κB activation drives B-cell lymphomagenesis HY Jin, M Lai, J Shephard, C Xiao Leukemia 30 (11), 2267-2270, 2016 | 5 | 2016 |
| Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study P Abrisqueta, E González-Barca, C Panizo, JMA Pérez, F Miall, ... The Lancet Haematology 11 (2), e136-e146, 2024 | 1 | 2024 |
Changchun XiaoSanofi Institute for Biomedical Research (SIBR), Suzhou, ChinaVerified email at scripps.edu
